Indometacin farnesil

Indometacin farnesil

Systematic (IUPAC) name
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	℞ Prescription only
Routes	Oral
Pharmacokinetic data
Metabolism	To indometacin
Half-life	1.5 hours
Excretion	Renal
Identifiers
CAS number	85801-02-1
ATC code	?
PubChem	CID 5282183
ChemSpider	4445378 Y
Chemical data
Formula	C34H40ClNO4
Mol. mass	562.14 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C34H40ClNO4/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-20-40-33(37)22-30-26(5)36(32-18-17-29(39-6)21-31(30)32)34(38)27-13-15-28(35)16-14-27/h9,11,13-19,21H,7-8,10,12,20,22H2,1-6H3/b24-11+,25-19+ Y Key:CFIGYZZVJNJVDQ-LMJOQDENSA-N Y
Y(what is this?)  (verify)

Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.

External links

• Infree prescribing information from Eisai Co.